Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Mar Pollut Bull ; 197: 115689, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37951120

RESUMO

Eelgrass (Zostera marina L.) is a key foundation species that provides multiple ecosystem services to shallow coastal and estuarine systems in the Northern Hemisphere. It is estimated that, over the last century, up to 50 % of all Z. marina habitat has been lost along the east coast of the USA due to factors including light reduction, eutrophication, and physical disturbance. Warming sea surface temperatures are also believed to be exacerbating losses and the future of this ecosystem is unclear. Here, we assess Z. marina meadows on Nantucket, an island system located 50 km off-shore of Massachusetts, by using common indicators of seagrass plant health and environmental quality. Our results show that Z. marina meadows on Nantucket Island are thermally stressed and light-limited during parts of their peak growing season. This suggests that sea-surface temperatures are a pivotal factor, along with cultural eutrophication, in observed large-scale losses of Z. marina and that further degradation could be expected in the future as the climate continues to warm. Methods from this study may be used by managers as a guide to assess seagrass ecosystem status in degrading systems.


Assuntos
Ecossistema , Zosteraceae , Temperatura , Clima , Estações do Ano
2.
Eur J Clin Pharmacol ; 73(3): 317-324, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27975131

RESUMO

PURPOSE: Individual variability in the endogenous CYP3A metabolite 4ß-hydroxycholesterol (4ßOHC) is substantial, but to which extent this is determined by genetic and nongenetic factors remains unclear. The aim of the study was to evaluate the explanatory power of candidate genetic variants and key nongenetic factors on individual variability in 4ßOHC levels in a large naturalistic patient population. METHODS: We measured 4ßOHC concentration in serum samples from 655 patients and used multiple linear regression analysis to estimate the quantitative effects of CYP3A4*22, CYP3A5*3, and POR*28 variant alleles, comedication with CYP3A inducers, inhibitors and substrates, sex, and age on individual 4ßOHC levels. RESULTS: 4ßOHC concentration ranged >100-fold in the population, and the multiple linear regression model explained about one fourth of the variability (R 2 = 0.23). Only comedication with inducers or inhibitors, sex, and POR genotype were significantly associated with individual variability in 4ßOHC level. The estimated quantitative effects on 4ßOHC levels were greatest for inducer comedication (+>313%, P < 0.001), inhibitor comedication (-34%, P = 0.021), and female sex (+30%, P < 0.001), while only a modestly elevated 4ßOHC level was observed in carriers vs. noncarriers of POR*28 (+11%, P = 0.023). CONCLUSIONS: These findings suggest that the CYP3A4*22, CYP3A5*3, and POR*28 variant alleles are of limited importance for overall individual variability in 4ßOHC levels compared to nongenetic factors.


Assuntos
Citocromo P-450 CYP3A/genética , Hidroxicolesteróis/sangue , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
3.
Clin Transl Sci ; 10(1): 42-49, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-27991741

RESUMO

Systemic inflammation has been linked to suppressed CYP3A(4) activity. We determined 4ß-hydroxycholesterol (4ßOHC), an endogenous CYP3A4 metabolite, in patients with rheumatoid arthritis (RA) before and after treatment with biological disease-modifying antirheumatic drugs (bDMARDs). The 4ßOHC was compared in 41 patients before and 2-5 months after initiating TNFα inhibitors (n = 31), IL-6 inhibitors (n = 5), or B-cell inhibitors (n = 5). Correlations between 4ßOHC and inflammatory markers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) were also tested before and after bDMARDs. 4ßOHC did not differ following bDMARD treatment (P = 0.6), nor in patients who started with IL-6 inhibitors (median 51.6 vs. 50.6 nmol/L). The 4ßOHC and CRP/ESR did not correlate before treatment (P > 0.5), but correlated significantly after bDMARDs (CRP = Spearman r -0.40; P < 0.01; ESR = r -0.34; P = 0.028) suggesting that mainly non-CYP3A4-suppressive cytokines were reduced during treatment. Thus, this study does not support a generally regained CYP3A4 phenotype in patients with RA following initiation of bDMARDs.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/sangue , Artrite Reumatoide/tratamento farmacológico , Hidroxicolesteróis/sangue , Inflamação/sangue , Adulto , Idoso , Artrite Reumatoide/complicações , Proteína C-Reativa/metabolismo , Feminino , Humanos , Inflamação/complicações , Inflamação/patologia , Masculino , Pessoa de Meia-Idade , Adulto Jovem
4.
Eur J Clin Pharmacol ; 72(9): 1099-104, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27353638

RESUMO

PURPOSE: Valproic acid (VPA) has an extensive interindividual pharmacokinetic variability. Published data regarding the impact of gender, age, and CYP2C9/2C19 genetics on VPA variability are conflicting, and the purpose of present study is to clarify the effect of these factors on dose-adjusted steady-state serum VPA concentration (C:D ratio) in a large, naturalistic patient material. METHODS: In patients who had been subjected to cytochrome P450 (CYP) genotyping and therapeutic drug monitoring of VPA, information about serum concentrations, dose, gender, age, and CYP2C9/2C19 genotypes was retrospectively collected from a routine TDM database during the period 2008-2012. The effects of age, gender, and CYP2C9/CYP2C19 genotypes on C:D ratios of VPA were investigated by multivariate analyses (mixed model) including sampling time as covariate. RESULTS: In total, 857 serum concentrations from 252 patients were included. A significant gender effect was observed with a 1.3-fold higher estimated C:D ratio in females than in males, i.e., geometric means 0.34 vs. 0.27 µM/mg/day, respectively (p < 0.001). A similar and significant difference in estimated geometric means was found between patients >65 vs. ≤65 years, i.e., 0.36 vs. 0.26 µM/mg/day (p < 0.001), respectively. Finally, no association between the various CYP2C9/2C19 variant genotypes and C:D ratio of VPA was observed (p > 0.1). CONCLUSION: The present study shows that age and gender significantly influence VPA serum concentration. In order to obtain similar drug exposure, our findings suggest that older female patients would generally require 30-50 % lower dosing of VPA compared to younger males. Moreover, we conclude that CYP2C9/2C19 genotype is not relevant for variability in VPA exposure.


Assuntos
Anticonvulsivantes/sangue , Citocromo P-450 CYP2C19/genética , Citocromo P-450 CYP2C9/genética , Ácido Valproico/sangue , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Anticonvulsivantes/farmacocinética , Monitoramento de Medicamentos , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Fatores Sexuais , Ácido Valproico/farmacocinética , Adulto Jovem
5.
Clin Pharmacol Ther ; 93(3): 275-82, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23361102

RESUMO

Individual variability in expression and function of organic anion-transporting polypeptide 1B1 (OATP1B1), multidrug resistance protein 1 (MDR1), and/or cytochrome P450 3A4 (CYP3A4) may impact the clinical response of many drugs. We investigated the correlation between expression of these proteins and pharmacokinetics of atorvastatin, a substrate of all three, in 21 obese patients with paired biopsies from liver and intestinal segments. The patients were also screened for the SLCO1B1 c.521T→C variant alleles. Approximately 30% (r(2) = 0.28) of the variation in oral clearance (CL/F) of atorvastatin was explained by hepatic OATP1B1 protein expression (P = 0.041). Patients carrying the SLCO1B1 c.521C variant allele (homozygous, n = 4; heterozygous, n = 2) exhibited 45% lower CL/F of atorvastatin than the c.521TT carriers (P = 0.067). No association between hepatic and intestinal expression of MDR1 or CYP3A4 and atorvastatin pharmacokinetics was found (P > 0.149). In conclusion, this study suggests that OATP1B1 phenotype is more important than CYP3A4 and MDR1 phenotypes for the individual pharmacokinetic variability of atorvastatin.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/fisiologia , Citocromo P-450 CYP3A/fisiologia , Ácidos Heptanoicos/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Mucosa Intestinal/metabolismo , Fígado/metabolismo , Obesidade/metabolismo , Transportadores de Ânions Orgânicos/fisiologia , Pirróis/farmacocinética , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/análise , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Adulto , Atorvastatina , Índice de Massa Corporal , Citocromo P-450 CYP3A/análise , Citocromo P-450 CYP3A/genética , Feminino , Humanos , Transportador 1 de Ânion Orgânico Específico do Fígado , Masculino , Pessoa de Meia-Idade , Transportadores de Ânions Orgânicos/análise , Transportadores de Ânions Orgânicos/genética
6.
Pharmacogenomics J ; 13(6): 544-50, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23147717

RESUMO

The widely used antipsychotic drug, olanzapine (OLA) shows large interindividual variability in metabolic clearance. Although the role of the enzymes CYP1A2, CYP2D6 and UGT1A4 has been extensively explored, little is known about the in vivo role of flavin-containing monooxygenases (FMOs) catalyzing the N-oxidation of OLA in vitro. We investigated the influence of FMO1 and 3 polymorphisms on the steady state serum concentrations of OLA and its N-oxide metabolite in 379 patients. The upstream FMO1*6 was associated with increased dose-adjusted serum OLA concentrations (C/Ds; P=0.008), an effect further enhanced by FMO1rs7877C>T in smokers. The influence of FMO3 polymorphisms was limited to variability in OLA N-oxide. Homozygous carriers of FMO3rs2266780A>G (p.E308G) displayed 50% lower C/D of OLA N-oxide compared with subjects homo- or heterozygous for the A-variant (P<0.003). Our data support the role of FMO3 in the N-oxidation of OLA and implicate for the first time the contribution of FMO1 and its functional *6 variant in OLA disposition.


Assuntos
Benzodiazepinas/sangue , Transtornos Mentais/tratamento farmacológico , Óxidos/sangue , Oxigenases/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Benzodiazepinas/uso terapêutico , Feminino , Humanos , Masculino , Transtornos Mentais/sangue , Transtornos Mentais/genética , Pessoa de Meia-Idade , Olanzapina , Polimorfismo de Nucleotídeo Único , Adulto Jovem
7.
Clin Pharmacol Ther ; 92(2): 221-7, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22713701

RESUMO

Olanzapine, a world leader in antipsychotic drugs, is used in the treatment of schizophrenia and bipolar disorder. There is considerable interpatient variability in its hepatic clearance. Polymorphic glucuronidation of olanzapine by uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4) was investigated retrospectively in patient samples taken for routine therapeutic drug monitoring (TDM) and in recombinant metabolic systems in vitro. Multivariate analyses revealed that patients who were heterozygous as well as those who were homozygous for the UGT1A4*3 allelic variant had significantly higher concentrations of the major metabolite olanzapine 10-N-glucuronide in serum (+38% (P = 0.011) and +246% (P < 0.001), respectively). This finding was in line with the significant increases in glucuronidation activity of olanzapine observed with recombinant UGT1A4.3 (Val-48) as compared with UGT1A4.1 (Leu-48) (1.3-fold difference, P < 0.001). By contrast, serum concentrations of the parent drug were not significantly influenced by UGT1A4 genotype. Our findings therefore indicate that UGT1A4-mediated metabolism is not a major contributor to interpatient variability in olanzapine levels. However, with respect to other drugs for which UGT1A4 has a dominant role in clearance, increased glucuronidation encoded by UGT1A4*3 might impact the risk for subtherapeutic drug exposure.


Assuntos
Antipsicóticos/farmacocinética , Benzodiazepinas/farmacocinética , Transtorno Bipolar/metabolismo , Glucuronídeos/metabolismo , Glucuronosiltransferase/metabolismo , Esquizofrenia/metabolismo , Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/genética , Feminino , Genótipo , Glucuronosiltransferase/genética , Humanos , Fígado/efeitos dos fármacos , Masculino , Taxa de Depuração Metabólica , Análise Multivariada , Noruega , Olanzapina , Estudos Retrospectivos , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética
8.
Drug Metab Dispos ; 37(12): 2340-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19773541

RESUMO

Systemic exposure of the antidepressant S-citalopram (escitalopram, SCIT) differs several-fold according to variable cytochrome P450 2C19 activity, demonstrating the importance of this enzyme for the metabolic clearance of SCIT in vivo. However, previous studies have indicated that the involvement of CYP2C19 in formation of the metabolite N-desmethyl S-citalopram (SDCIT) is limited. Therefore, the purpose of the present in vitro study was to investigate to what extent the CYP2C19-mediated clearance of SCIT was due to a metabolic pathway different from N-desmethylation and to identify the product(s) of this possible alternative metabolic reaction. CYP2C19-mediated metabolism of SCIT was investigated using recombinant Supersomes expressing human CYP2C19. Initial experiments showed that approximately half of the CYP2C19-mediated clearance of SCIT was accounted for by the N-desmethylation pathway. Subsequent experiments identified that, in addition to SDCIT, the propionic acid metabolite of SCIT (SCIT PROP) was formed by CYP2C19 in vitro. Formation of SCIT PROP accounted for 35% of total CYP2C19-mediated clearance of SCIT (calculated as the ratio between metabolite formation rate and substrate concentration at low substrate concentration). Moreover, analysis of samples from six CYP2C19-genotyped patients treated with SCIT indicated that differences in serum concentrations of SCIT between CYP2C19 genotypes may be due to a combined effect on SCIT PROP and SDCIT formation. Identification of SCIT PROP as a metabolic pathway catalyzed by CYP2C19 might explain why impaired CYP2C19 activity has a substantially larger effect on SCIT exposure than estimated from in vitro data based solely on formation of SDCIT.


Assuntos
Antidepressivos de Segunda Geração/metabolismo , Hidrocarboneto de Aril Hidroxilases/metabolismo , Citalopram/metabolismo , Inibidores Seletivos de Recaptação de Serotonina/metabolismo , Adulto , Antidepressivos de Segunda Geração/sangue , Hidrocarboneto de Aril Hidroxilases/genética , Biotransformação , Citalopram/análogos & derivados , Citalopram/sangue , Citocromo P-450 CYP2C19 , Remoção de Radical Alquila , Feminino , Genótipo , Humanos , Cinética , Masculino , Microssomos/enzimologia , Pessoa de Meia-Idade , Modelos Biológicos , Fenótipo , Propionatos/metabolismo , Proteínas Recombinantes/metabolismo , Inibidores Seletivos de Recaptação de Serotonina/sangue
9.
Eur J Clin Pharmacol ; 64(12): 1181-8, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18677622

RESUMO

OBJECTIVE: To investigate the impact of CYP2C19 genotype on serum concentrations of sertraline and N-desmethyl sertraline in psychiatric patients. METHODS: Patients treated with sertraline (n = 121) were divided into six subgroups according to CYP2C19 genotype: CYP2C19*17/*17, CYP2C19*1/*17, CYP2C19*1/*1, CYP2C19*17/def, CYP2C19*1/def and CYP2C19def/def (def = allele encoding defective CYP2C19 metabolism, i.e. *2 and *3). Dose-adjusted serum concentrations were compared by linear mixed model analyses using the CYP2C19*1/*1 subgroup as reference. RESULTS: Subgroups carrying one or two alleles encoding defective CYP2C19 metabolism achieved significantly higher mean dose-adjusted serum concentrations of sertraline and N-desmethyl sertraline compared to the CYP2C19*1/*1 subgroup (P < 0.05). The effect of CYP2C19 genotype was expressed as 3.2-fold (sertraline) and 4.5-fold (N-desmethyl sertraline) higher dose-adjusted serum concentrations in the CYP2C19def/def subgroup compared to the CYP2C19*1/*1 subgroup (P < 0.01). The CYP2C19*17 allele had no influence on the dose-adjusted serum concentrations of sertraline and N-desmethyl sertraline. CONCLUSION: The significantly higher serum concentrations associated with alleles encoding defective CYP2C19 metabolism might be of relevance for the clinical outcome of sertraline treatment.


Assuntos
Antidepressivos/sangue , Hidrocarboneto de Aril Hidroxilases/genética , Variação Genética , Transtornos Mentais , Sertralina/análogos & derivados , Adulto , Antidepressivos/farmacocinética , Antidepressivos/uso terapêutico , Cromatografia Líquida de Alta Pressão , Citocromo P-450 CYP2C19 , Feminino , Genótipo , Humanos , Masculino , Transtornos Mentais/sangue , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/genética , Taxa de Depuração Metabólica/genética , Pessoa de Meia-Idade , Sertralina/sangue , Sertralina/farmacocinética , Sertralina/uso terapêutico , Espectrometria de Massas em Tandem
10.
Clin Pharmacol Ther ; 83(2): 322-7, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17625515

RESUMO

Recently, a novel allelic variant of cytochrome P450 2C19 encoding ultrarapid enzyme activity was described (denoted CYP2C19*17). The objective of this study was to evaluate the impact of CYP2C19*17 on serum concentration of escitalopram in psychiatric patients. One hundred and sixty-six patients treated with escitalopram were divided into the following subgroups according to CYP2C19 genotype: CYP2C19*17/*17 (n=7), CYP2C19*1/*17 (n=43), CYP2C19*1/*1 (n=60), CYP2C19*17/def (n=16), CYP2C19*1/def (n=34), and CYP2C19def/def (n=6) (def=defective allele, i.e., CYP2C19*2 or *3). Dose-adjusted serum concentrations of escitalopram were compared using the CYP2C19*1/*1 subgroup as reference. Geometric mean of the escitalopram serum concentration was 42% lower in patients homozygous for CYP2C19*17 (P<0.01) and 5.7-fold higher in subjects homozygous for defective CYP2C19 alleles (P<0.001). Of the heterozygous subgroups, only CYP2C19*1/def was significantly different from CYP2C19*1/*1 (P<0.001). In conclusion, a homozygous CYP2C19*17 genotype is associated with lower serum concentration of escitalopram, which might imply increased risk of therapeutic failure.


Assuntos
Antidepressivos de Segunda Geração/farmacocinética , Hidrocarboneto de Aril Hidroxilases/genética , Citalopram/farmacocinética , Transtornos Mentais/tratamento farmacológico , Oxigenases de Função Mista/genética , Polimorfismo Genético , Inibidores Seletivos de Recaptação de Serotonina/farmacocinética , Adulto , Antidepressivos de Segunda Geração/administração & dosagem , Antidepressivos de Segunda Geração/sangue , Hidrocarboneto de Aril Hidroxilases/metabolismo , Citalopram/administração & dosagem , Citalopram/sangue , Citocromo P-450 CYP2C19 , Feminino , Frequência do Gene , Genótipo , Heterozigoto , Homozigoto , Humanos , Masculino , Transtornos Mentais/enzimologia , Transtornos Mentais/genética , Pessoa de Meia-Idade , Oxigenases de Função Mista/metabolismo , Fenótipo , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/sangue , Falha de Tratamento
11.
Pharmacopsychiatry ; 39(4): 121-7, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16871467

RESUMO

In therapeutic drug monitoring (TDM) practice of psychotropic agents, it is common to summarize plasma concentrations of parent drugs and metabolites when these are considered equipotent. However, there is no clear definition of the term equipotent and one should be aware that metabolites referred to as equipotent in the literature could display several-fold differences in affinities toward target proteins. The fact that the parent drug and metabolite may have different abilities to penetrate the blood-brain-barrier further complicates the picture. Potential differences in brain distribution imply that various metabolite/drug ratios representing the same total concentration in plasma reflect different active concentrations in the brain. Plasma metabolite/drug ratios could differ extensively according to metabolic phenotype and administration route. An example is risperidone where the plasma metabolite/drug ratio is 30-fold lower in cytochrome P450 2D6 poor metabolizers compared to ultrarapid metabolizers, and four-fold lower after intramuscular compared to oral administration. As risperidone is more lipophilic and less effluxed by P-glycoprotein in the blood-brain-barrier than the active metabolite 9-hydroxyrisperidone, one might speculate that patients with high plasma metabolite/drug ratios obtain lower active concentrations in the brain. However, the relative drug-metabolite brain distribution needs to be quantified in humans to clarify to what degree drug and metabolite plasma levels reflect active brain concentrations. The present review illustrates the complexity of active metabolites in TDM with focus on amitriptyline, clomipramine, doxepin, imipramine, fluoxetine, venlafaxine and risperidone, all psychotropic drugs where target plasma concentration ranges are based on the sum of parent drug and metabolite. In addition, perspectives on the possibility of using distribution- and activity-weighted plasma concentrations are provided.


Assuntos
Encéfalo/metabolismo , Monitoramento de Medicamentos/métodos , Psicotrópicos/farmacocinética , Humanos , Individualidade , Transtornos Mentais/sangue , Transtornos Mentais/tratamento farmacológico , Psicotrópicos/sangue
12.
Eur J Clin Pharmacol ; 58(10): 663-8, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12610742

RESUMO

OBJECTIVE: The oral availability of many drugs metabolised by the enzyme cytochrome P(450) 3A4 (CYP3A4) is increased if co-administered with grapefruit juice. Extracts from grapefruit peel have also demonstrated inhibitory activity and, during commercial manufacturing of grapefruit juice, inhibitory components might be squeezed into the juice from the peel. Thus, the aim of this in vitro study was to identify CYP3A4 inhibitors in grapefruit peel. METHODS: Grapefruit peel was extracted with diethyl ether, and the extract was further fractionated by normal-phase chromatography. Fractions demonstrating significant CYP3A4 inhibitory activity, as measured by the relative reduction in N-demethylation of diltiazem in transfected human liver epithelial cells, were subsequently separated by preparative thin-layer chromatography. Constituents of the fractions and isolated compounds were identified by nuclear magnetic resonance spectroscopy. Analysis of diltiazem and N-demethyl-diltiazem was performed using high-performance liquid chromatography. RESULTS: Of the identified components in grapefruit peel, only epoxybergamottin demonstrated a concentration-dependent inhibition of the CYP3A4-mediated N-demethylation of diltiazem. The IC(50) value was calculated to be 4.2+/-1.1 micro M. Coumarins without the furan ring and flavonoids isolated from grapefruit peel did not interfere with the metabolism of diltiazem. The results indicated the presence of other CYP3A4 inhibitors in grapefruit peel, but these agents were lost during the purification process excluding their identification. CONCLUSION: The furanocoumarin epoxybergamottin, present in grapefruit peel, is an inhibitor of CYP3A4. In commercial manufacturing of grapefruit juice, epoxybergamottin is possibly distributed into the juice. During manufacturing, however, epoxybergamottin may be hydrolysed to 6',7'-dihydroxybergamottin, which has been suggested as an important CYP3A4 inhibitor in grapefruit juice.


Assuntos
Citrus paradisi , Inibidores das Enzimas do Citocromo P-450 , Frutas/química , Furocumarinas/química , Furocumarinas/isolamento & purificação , Células Cultivadas , Cromatografia Líquida de Alta Pressão , Cumarínicos/isolamento & purificação , Cicloexenos , Citocromo P-450 CYP3A , Diltiazem/farmacocinética , Flavonoides/isolamento & purificação , Furocumarinas/farmacologia , Humanos , Limoneno , Espectroscopia de Ressonância Magnética , Extratos Vegetais/química , Extratos Vegetais/farmacologia , Terpenos/isolamento & purificação
13.
Tidsskr Nor Laegeforen ; 121(2): 189-93, 2001 Jan 20.
Artigo em Norueguês | MEDLINE | ID: mdl-11475198

RESUMO

BACKGROUND: Isoenzymes of the cytochrome P450 (CYP) system play a prominent role in drug metabolism, including the HMG-CoA reductase inhibitors (statins). Alteration in metabolic activity is often the underlying mechanism of clinically relevant interactions, thus it is important to make a rational assessment of the risk for metabolic interactions with statins. MATERIAL AND METHODS: Articles covering the field of statin metabolism and related interactions were mainly searched for via PubMed. RESULT: More than 50% of the overall CYP metabolism is mediated through the isoenzyme CYP3A4, which is the main elimination route of simvastatin, lovastatin and atorvastatin. Interaction studies reveal that simvastatin and lovastatin have the highest potential for clinically relevant interactions related to this isoenzyme, most often leading to increased efficacy/toxicity of the statin. Interactions with agents that alter the activity of CYP3A4 can also be expected for atorvastatin. Other statins are to a lesser extent dependent on CYP3A4 in their elimination. Thus, pravastatin, cerivastatin and fluvastatin have a minor potential for interactions linked to this isoenzyme. Interactions associated with CYP2C9-interference may, however, be present for fluvastatin. INTERPRETATION: Since lipid-lowering therapy most often is life-long, the use of statins will frequently be accompanied by the use of multiple drugs, hence the importance of considering the risk for interactions when selecting statins.


Assuntos
Anticolesterolemiantes/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo , Antibacterianos/efeitos adversos , Antibacterianos/metabolismo , Anticolesterolemiantes/efeitos adversos , Anticoagulantes/efeitos adversos , Anticoagulantes/metabolismo , Azóis/efeitos adversos , Azóis/metabolismo , Bebidas/efeitos adversos , Bloqueadores dos Canais de Cálcio/efeitos adversos , Bloqueadores dos Canais de Cálcio/metabolismo , Citrus , Ciclosporina/efeitos adversos , Ciclosporina/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Interações Medicamentosas , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Imunossupressores/efeitos adversos , Imunossupressores/metabolismo , Macrolídeos , Fatores de Risco , Varfarina/efeitos adversos , Varfarina/metabolismo
14.
Drug Metab Dispos ; 28(2): 107-9, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10640504

RESUMO

The objective of this in vitro study was to investigate both the intestinal metabolism and transport of diltiazem (DTZ) and its major metabolites in rat jejunum. Metabolism experiments were performed with everted sacs, whereas sheets mounted in a symmetrical twin chamber system were used in transport studies. DTZ was rapidly desacetylated by the rat jejunum to the principle metabolite desacetyl-diltiazem (M1). In addition, minor amounts of N-demethyl-diltiazem and desacetyl-N-demethyl-diltiazem were formed. Due to the rapid desacetylation, it proved difficult to study the transport of DTZ in this model. However, the primary metabolite M1 was shown to be subjected to P-glycoprotein (Pgp)-mediated efflux. The flux rate of M1 was 6- to 7-fold higher from the serosal to the luminal compartment than in the opposite direction. Both coadministration of verapamil and Pgp monoclonal antibody dose dependently increased luminal-to-serosal flux and decreased serosal-to-luminal flux. In conclusion, rat jejunum metabolizes DTZ extensively in vitro, and the major primary metabolite M1 is subjected to Pgp-mediated efflux.


Assuntos
Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo , Bloqueadores dos Canais de Cálcio/farmacocinética , Diltiazem/análogos & derivados , Jejuno/metabolismo , Animais , Disponibilidade Biológica , Transporte Biológico , Biotransformação , Remoção de Radical Alquila , Diltiazem/farmacocinética , Hidrólise , Técnicas In Vitro , Absorção Intestinal , Masculino , Ratos , Ratos Wistar
15.
Eur J Clin Pharmacol ; 56(8): 575-9, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11151747

RESUMO

OBJECTIVE: In a previous study of diltiazem (DTZ) pharmacokinetics in renal transplant patients, we speculated that a polymorphic enzyme could be involved in O-demethylation of diltiazem. The aim of this in vitro study was to investigate whether O-demethylation of DTZ is mediated by cytochrome P450-2D6 (CYP2D6). METHODS: DTZ was incubated with transfected human liver epithelial (THLE) cells expressing CYP2D6 (T5-2D6 clone). Metabolism of DTZ was studied over a concentration range of 12.5-400 microM and in the presence of quinidine (a CYP2D6 inhibitor) or erythromycin (a CYP3A4 inhibitor). THLE cells lacking CYP2D6 activity (T5-neo clone) were used as control. The culture medium of the cells, in which DTZ was dissolved, was analysed for DTZ and metabolites prior to and after 8 h of incubation using high-performance liquid chromatography (HPLC, UV detection). Authentic O-demethyl-DTZ (Mx) was not available, and this metabolite was therefore not identifiable. RESULTS: Desacetyl-O-demethyl-DTZ (M4) was exclusively produced during incubations of DTZ with THLE cells expressing CYP2D6. The rate of M4 formation was described using Michaelis Menten kinetics in the concentration range of DTZ used. Production of M4 was inhibited by quinidine, but not erythromycin. An unidentified chromatographic peak, which was interpreted to be Mx, showed the same pattern of formation as M4 both in absence and presence of inhibitors. N-demethylated metabolites, formed by CYP3A4, were not observed in any of the cell lines. CONCLUSION: Evidence was provided in vitro that O-demethylation of DTZ is mediated by the polymorphic isoenzyme CYP2D6. Involvement of CYP2D6 in the metabolism of DTZ may have clinical implications regarding pharmacokinetic variability and interactions.


Assuntos
Bloqueadores dos Canais de Cálcio/metabolismo , Citocromo P-450 CYP2D6/metabolismo , Diltiazem/metabolismo , Hepatócitos/enzimologia , Acetilação , Bloqueadores dos Canais de Cálcio/farmacocinética , Citocromo P-450 CYP2D6/genética , Diltiazem/farmacocinética , Células Epiteliais/enzimologia , Células Epiteliais/metabolismo , Hepatócitos/metabolismo , Humanos , Cinética , Metilação , Transfecção
16.
Eur J Clin Pharmacol ; 55(5): 383-7, 1999 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10456488

RESUMO

OBJECTIVE: Bilateral cyclosporin A (CsA) and diltiazem pharmacokinetic interactions have previously been investigated, however, not with the new microemulsion preconcentrate formulation of CsA (Sandimmun Neoral). In addition, the pharmacokinetic effects on the pharmacological active metabolites of diltiazem have not previously been investigated. We performed a pharmacokinetic interaction study in renal transplant recipients, measuring both unmetabolised CsA and diltiazem in addition to three of the main metabolites of diltiazem (MA, M1, M2). METHODS: Nine CsA-treated renal transplant patients were treated with diltiazem, 90-120 mg b.i.d., for 4 weeks. Pharmacokinetic investigations were performed both before and at the end of the diltiazem treatment period. Six non-CsA-treated renal transplant patients served as controls of CsA interactions with diltiazem and its metabolites. RESULTS: Diltiazem treatment resulted in a significant mean increase in the area under the concentration time curve (AUC) for CsA of 51(8)% (P < 0.008) and a peak concentration (Cmax) of 34(8)% (P < 0.05), without altering time to peak concentration (tmax). CsA, however, did not significantly influence diltiazem pharmacokinetics, though two of the metabolites (M1 and M2) tended to be increased. CONCLUSIONS: Diltiazem interacts significantly with the pharmacokinetics of CsA in the new microemulsion formulation. Microemulsion-formulated CsA, however, did not show significant interaction with diltiazem pharmacokinetics.


Assuntos
Ciclosporina/farmacocinética , Diltiazem/metabolismo , Inibidores Enzimáticos/farmacocinética , Transplante de Rim/fisiologia , Rim/metabolismo , Adulto , Idoso , Anti-Hipertensivos/sangue , Anti-Hipertensivos/metabolismo , Anti-Hipertensivos/farmacocinética , Ciclosporina/administração & dosagem , Ciclosporina/sangue , Diltiazem/sangue , Diltiazem/farmacocinética , Interações Medicamentosas , Emulsões , Inibidores Enzimáticos/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA